Skip to main content

Table 5 IC50 of combination treatment of NaDCM (1.5 μg/mL) with various concentration of antiHCV drug

From: An in vitro study of an Artocarpus heterophyllus substance as a hepatitis C antiviral and its combination with current anti-HCV drugs

NaDCM (1.5 μg/mL)
Ribavirin Cyclosporin
Conc (ug/mL) IC50 combination treatment Conc (ug/mL) IC50 combination treatment
40.00 < 0,1 Syn 2.40 < 0,03 Syn
20.00 < 0,1 Syn 1.20 0,03 ± 0,03 Syn
10.00 0.32 Syn 0.60 0,19 ± 0,12 Syn
5.00 0.47 Syn 0.30 1,20 ± 0,60 Ant
2.50 0,4 ± 0,3 Syn 0.10 1,63 ± 0,17 Ant
NaDCM (1.5 μg/mL)
Simaprevir Telaprevir
Conc (nM) IC50 combination treatment Conc (nM) IC50 combination treatment
160.00 < 0,7 Syn 40.00 0,21 ± 0,15 Ant
80.00 < 0,7 Syn 20.00 0,75 ± 0,06 Ant
40.00 < 0,7 Syn 10.00 0,9 ± 0,1 Ant
20.00 < 0,7 Syn 5.00 1,42 ± 0,07 Ant
10.00 0,83 ± 0,33 Ant 2.50 1,22 ± 0,09 Ant
  1. Syn Synergism effect, Ant Antagonist effect